Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Feb 28;3(1):1-5.
doi: 10.35772/ghm.2021.01010.

COVID-19 vaccines: implementation, limitations and opportunities

Douglas D Richman  1
Affiliations
Editorial

COVID-19 vaccines: implementation, limitations and opportunities

Douglas D Richman. Glob Health Med. .

Abstract

The speed of development and the magnitude of efficacy of recently developed vaccines directed against SARS-CoV-2 has been truly remarkable. This editorial will not summarize the highly publicized and reviewed information about the design and clinical trial results of these vaccines. Rather, I will speculate about several issues regarding i) considerations of the rollout and implementation of the multiple vaccines, ii) the use of the vaccines in ways different from those used in the registrational phase 3 studies, iii) the future both of SARS-CoV-2 in the human population and of "normal" human life returning after widespread vaccination, and iv) the implications of the success of these SARS-CoV-2 vaccines for vaccine development against other pathogens.

Keywords: COVID-19; SARS-CoV-2; vaccine.

PubMed Disclaimer

Conflict of interest statement

The author has no conflict of interest to disclose.

References

    1. Cohen J. Shots of hope. Science. 2020; 370:1392-1394. - PubMed
    1. Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021; 21:73-82. - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, et al. . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383:2603-2615. - PMC - PubMed
    1. Baden LR, El Sahly HM, Essink B, et al. . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021; 384:403-416. - PMC - PubMed
    1. Voysey M, Clemens SAC, Madhi SA, et al. . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021; 397:99-111. - PMC - PubMed

Publication types

LinkOut - more resources